# Par Drugs And Chemicals (NSE: PAR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/PAR · Pivot · prices to 21 Oct 2026

Par Drugs And Chemicals (NSE: PAR) closed at ₹105.00 on 21 Oct 2026. With a market capitalisation of ₹116 Cr, it ranks 2406th by market cap among the 3,928 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 13.5% in FY25. Its 52-week range is ₹78.05 (30 Mar 2026) to ₹180.00 (3 Sep 2026); the last close is 41.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹20 Cr (−12.2% year on year) and net profit ₹1 Cr (−48.5%), on a standalone basis. Promoters held 73.41% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹105.00 |
| Market cap | ₹116 Cr |
| ROE | 13.5% (FY25) |
| ROCE | 17.5% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹180.00 (3 Sep 2026) |
| 52-week low | ₹78.05 (30 Mar 2026) |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹20 Cr | −12.2% | ₹1 Cr | −48.5% | ₹0.69 |
| Q3 FY26 | ₹29 Cr | +37.2% | ₹5 Cr | +727.6% | ₹3.90 |
| Q2 FY26 | ₹29 Cr | −17.3% | ₹4 Cr | −52.0% | ₹3.36 |
| Q1 FY26 | ₹26 Cr | +15.2% | ₹3 Cr | +31.6% | ₹2.70 |
| Q4 FY25 | ₹22 Cr | −2.1% | ₹2 Cr | −55.6% | ₹1.34 |
| Q3 FY25 | ₹21 Cr | −10.9% | ₹1 Cr | −83.0% | ₹0.47 |
| Q2 FY25 | ₹35 Cr | +33.9% | ₹9 Cr | +75.9% | ₹6.99 |
| Q1 FY25 | ₹23 Cr | −1.4% | ₹3 Cr | +2.4% | ₹2.06 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹101 Cr | ₹13 Cr |
| FY24 | ₹96 Cr | ₹15 Cr |
| FY23 | ₹96 Cr | ₹11 Cr |
| FY22 | ₹75 Cr | ₹9 Cr |
| FY21 | ₹61 Cr | ₹12 Cr |
| FY20 | ₹56 Cr | ₹5 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 73.41%
- Domestic institutions: 0.09%
- Non-institutions: 26.51%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Lactose India](https://app.pivotnow.in/stock/LACTOSE) | — | ₹132 Cr | — | — |
| [Valencia Nutrit](https://app.pivotnow.in/stock/VALENCIA) | — | ₹132 Cr | — | — |
| [BALAXI PHARMACEUTICALS](https://app.pivotnow.in/stock/BALAXI) | — | ₹130 Cr | — | — |
| [Aspira Pathlab](https://app.pivotnow.in/stock/ASPIRA) | — | ₹125 Cr | — | — |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [Pharmaids Pharm](https://app.pivotnow.in/stock/PHARMAID) | — | ₹113 Cr | — | — |

## Questions and answers

### What is the share price of Par Drugs And Chemicals today?

Par Drugs And Chemicals (NSE: PAR) last closed at ₹105.00 on 21 Oct 2026. Its 52-week high is ₹180.00 and its 52-week low is ₹78.05.

### What is the market cap of Par Drugs And Chemicals?

Par Drugs And Chemicals' market capitalisation is ₹116 Cr (₹116 Cr) at the — close, ranking 2406th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Par Drugs And Chemicals?

Return on equity was 13.5% in FY25 and return on capital employed was 17.5% in FY25 (standalone figures).

### Is Par Drugs And Chemicals a debt-free company?

Par Drugs And Chemicals is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Par Drugs And Chemicals' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Par Drugs And Chemicals reported revenue of ₹20 Cr, −12.2% year on year, and net profit of ₹1 Cr, −48.5% year on year.

### What is the shareholding pattern of Par Drugs And Chemicals?

As of 30 Jun 2026: promoters 73.41%, domestic institutions 0.09%, non-institutions 26.51%.

### Who are Par Drugs And Chemicals' competitors?

The listed Pharma & Healthcare companies closest to Par Drugs And Chemicals by market cap are Lactose India, Valencia Nutrit, BALAXI PHARMACEUTICALS, Aspira Pathlab, Godavari Drugs and Pharmaids Pharm.

### Is Par Drugs And Chemicals a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Par Drugs And Chemicals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PAR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.